---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-027998"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:36:18.797642+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD full-year 2023 net loss $7.7M, cash $4.3M; strategic review ongoing

## Summary
- Net loss from continuing operations $(7.7)M ($(0.74) per share) vs $1.1M income ($0.12) in 2022.
- Gross license royalties $4.5M under Mayne License; net recognized $1.3M revenue and $0.5M other income.
- Operating expenses fell 85.4% to $9.8M, reflecting transition from commercial pharma to royalty model.
- Cash and equivalents $4.3M at Dec 31, 2023; company continues exploring strategic alternatives.

## SEC filing metadata
- accession: 0001213900-24-027998
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390024027998/0001213900-24-027998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390024027998/ea0202833-8k_therape.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-027998
- JSON: https://secwatch.observer/filing/0001213900-24-027998.json
- Plain text: https://secwatch.observer/filing/0001213900-24-027998.txt

## Key facts
- Earnings Releases
  TherapeuticsMD, Inc. reported the full year ended December 31, 2023 results: net income Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, EPS $(0.74) per basic and diluted common share.
  - Period: the full year ended December 31, 2023
  - Net income: Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share
  - EPS: $(0.74) per basic and diluted common share
  - Result: reported results
  source text: TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000121390024027998/0001213900-24-027998-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.